USPH Stock Forecast & Price Target

US Physical Therapy is supported by resilient demand, with 1Q26 revenue of $198.3M and EBITDA of $20.2M despite weather-related headwinds that cut more than 31,000 visits, while same-store PT revenue rose 2.5% and daily visits increased to 31.8. Its outlook is strengthened by improving pricing, including a net PT rate gain of about 1% Y/Y and commercial rate lift above 3%, plus a fast-growing IIP segment that generated $30.6M of revenue, up 11.8% Y/Y, with margin expansion. Investors also see meaningful upside from hospital partnerships, accretive acquisitions, and a manageable balance sheet with $28M cash, $205M debt, and net debt to annualized EBITDA of 2.2x.

US Physical Therapy is facing a negative fundamental outlook because continued clinician wage pressure could squeeze clinic-level margins and weigh on overall profitability. Medicare reimbursement pressure is another major risk, especially since Medicare represents roughly a third of revenue, making current profitability assumptions look aggressive if rate pressure persists. An economic contraction could further reduce demand for physical therapy services and slow growth in the industrial injury prevention segment, which relies heavily on manufacturing customers.